Outlining Risk Factor Identification and Mitigation in Bladder Cancer

Commentary
Video

Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.

CancerNetwork® spoke with Armine K. Smith, MD, assistant professor of Urology and director of Urologic Oncology at Sibley Memorial Hospital, part of Johns Hopkins Medicine, about risk factors related to bladder cancer, as well as approaches to help mitigate them.

Smith initially touched upon well-established risk factors, identifying smoking, exposure to chemicals used in dye and rubber industries, and chronic bladder inflammation as the most common risk factors. Additionally, she explained that a minority of patients have a genetic predisposition to forming bladder tumors as well.

She then outlined some preventative measures patients can take to mitigate the risk of bladder cancer, including smoking cessation or abstention, minimizing chemical exposure, and the presence and utilization of a program for early detection of bladder cancers, particularly among patients at a higher risk for developing the disease.

Smith further expressed that ongoing research is seeking to elucidate whether other environmental exposures, which are not typically associated with bladder cancer risk, may actually impact the development of the disease. Finally, she stated that research may also uncover the role of microbiomes in the development of bladder tumors and their response to treatment.

Transcript:

To even summarize, there are well-established risk factors, such as smoking, exposure to some chemicals that are used in the dye and rubber industries, chronic bladder inflammation, [and] there is a minority of patients who have a genetic predisposition to forming bladder tumors. Preventative measures include smoking cessation, or never smoking, if possible, minimizing chemical exposures when possible, and then having a program for detecting these cancers earlier and [for] patients at risk.

Ongoing research also suggests there might be some other environmental exposures that are not usually associated with bladder cancer and more information to come, [as well as] the role of microbiome in developing these cancers and responses to the treatments for these cancers.

Recent Videos
Treatment with AML depends on a variety of factors, including stage of treatment, transplant eligibility, and mutational status.
Experts weigh in on tumor-informed testing, false positives, relevant trial data, and other key concepts related to circulating tumor DNA.
Oncologists are still working on management strategies for neuropathy; a common adverse effect related to chemotherapeutics for ovarian cancer.
CAR T-cell therapies or other agents that impact the immune system in the long term may be important to keep in mind for the management of SCLC.
Marc S. Raab, MD, PhD, details how agents like carfilzomib may play a role in treatment after progression on teclistamab-based induction therapy.
Genetic testing information can be used to risk-stratify ovarian cancer survivors for breast cancer, particularly those with BRCA1 or BRCA2 mutations.
Patients with mantle cell lymphoma who are older and have less fitness may be eligible for regimens that include bendamustine/rituximab.
Employing patient-reported outcomes may help include those with small cell lung cancer in the shared decision-making process.
Related Content